Evaluation of the Efficacy of a Recombinant Simian Varicella Virus Vaccine Expressing Simian Immunodeficiency Virus Envelope and Capsid Proteins by Wichman, Thomas G
University of Mississippi
eGrove
Honors Theses Honors College (Sally McDonnell BarksdaleHonors College)
2019
Evaluation of the Efficacy of a Recombinant Simian
Varicella Virus Vaccine Expressing Simian
Immunodeficiency Virus Envelope and Capsid
Proteins
Thomas G. Wichman
University of Mississippi
Follow this and additional works at: https://egrove.olemiss.edu/hon_thesis
Part of the Biology Commons
This Undergraduate Thesis is brought to you for free and open access by the Honors College (Sally McDonnell Barksdale Honors College) at eGrove. It
has been accepted for inclusion in Honors Theses by an authorized administrator of eGrove. For more information, please contact egrove@olemiss.edu.
Recommended Citation
Wichman, Thomas G., "Evaluation of the Efficacy of a Recombinant Simian Varicella Virus Vaccine Expressing Simian
Immunodeficiency Virus Envelope and Capsid Proteins" (2019). Honors Theses. 1007.
https://egrove.olemiss.edu/hon_thesis/1007
 i 
EVALUATION OF THE EFFICACY OF A RECOMBINANT SIMIAN VARICELLA 
VIRUS VACCINE EXPRESSING SIMIAN IMMUNODEFICIENCY VIRUS 
ENVELOPE AND CAPSID PROTEINS 
 
 
 
 
 
By 
Thomas Grant Wichman 
 
 
 
 
 
A thesis submitted to the faculty of The University of Mississippi in partial fulfillment of 
the requirements of the Sally McDonnell Barksdale Honors College. 
 
 
 
 
 
Oxford 
May 2019 
 
 
 
 
 
Approved by: 
 
 
________________________________ 
Advisor: Dr. Wayne Gray 
 
________________________________ 
Reader: Dr. Brian Doctor 
 
________________________________ 
Reader: Dr. Patrick Curtis
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ó 2019 
Thomas Grant Wichman 
ALL RIGHTS RESERVED 
 iii 
DEDICATION 
 
I would like to dedicate this Capstone Project to my parents, John and Sharmon 
Wichman. I am more than lucky to have parents who constantly love and support me in 
anything that I do. It is because of them that I had the privilege to come to The University 
of Mississippi and can now culminate that time into my senior thesis for the Sally 
McDonnell Barksdale Honors College.   
 iv 
ACKNOWLEDGEMENTS 
 
 
 
I first would like to thank Dr. Wayne L. Gray and The University of Mississippi Biology 
Department for the opportunity to participate in this research project, and to use this 
virology lab to expand my own knowledge. Dr. Gray’s innovation and willingness to 
teach at all scales has been both beneficial and inspiring to me during my time at Ole 
Miss. 
 
I also would like to extend my thanks to Michael Hohl for always being willing to take 
time to answer my questions and guide me throughout new or complex lab protocols 
required for my thesis research. 
 
I finally would like to thank the Honors College for the numerous opportunities 
throughout college to expand my academic career, and my thesis committee for taking 
time to read, edit, and further improve this manuscript.   
 
This study was funded by NIH grant R01-AI123029 and NIH Contract 
HHSN272201300041.  
 
 
 v 
ABSTRACT 
THOMAS GRANT WICHMAN: Evaluation of the Efficacy of a Recombinant Simian 
Varicella Virus Expressing Simian Immunodeficiency Virus Envelope and Capsid 
Proteins 
(Under the direction of Dr. Wayne L. Gray) 
 
 
 
 Human Immunodeficiency Virus (HIV) is a retrovirus that infects CD4+ T-
lymphocytes, which when left untreated, later develops into Acquired Immunodeficiency 
Syndrome (AIDS). Up to 25,000 people die every week from AIDS infection, making 
HIV and AIDS research a very high priority for virologists. While highly researched by 
scholars around the world, no person has been able to develop a successful vaccine, as 
the retroviral nature of the virus and its high mutation rate make vaccine development 
incredibly difficult. However, recombinant genetic technology will hopefully allow the 
revolutionization of vaccines which have already proven effective in immunization. The 
already developed varicella-zoster virus (VZV) vaccine’s safety, effectiveness, and 
infection range limited to humans make it a great vector for the creation of a recombinant 
HIV Vaccine. In this study, simian varicella virus (SVV) and simian immunodeficiency 
virus (SIV) act as a model to evaluate a recombinant vaccine’s effectiveness on non-
human primates’ humoral responses.   
 The wide-scale goal of HIV and concurrent AIDS and SIV research is to both 
cure and prevent these diseases; in the research this thesis follows, the aim is to create a 
recombinant SVV vaccine which can manifest immunity in non-human primates, with 
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hopes to parallel that research for a similar vaccine for human use.  The specific aims of 
this thesis include: the development of an optimal protocol for antibody response 
analysis, and the evaluation of the efficacy of a recombinant SVV vaccine expressing 
SIV gag and env proteins, either with a protein boost or a DNA boost. After the protocol 
was modified and optimized, sera from rhesus macaques at different points throughout 
their immunization schedules were analyzed via western blot. Results showed that the 
prime-boost schedule is effective in inducing an antibody-mediated response, specifically 
after boosting, and that a protein vaccine boost rather than DNA vaccine boost is the most 
effective. This model will continue to be researched further in hopes of developing a 
successful SIV, and subsequently, HIV vaccine.  
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INTRODUCTION 
 
 Since as early as the 18th century, when Edward Jenner developed the world’s 
first vaccine, one that would later eradicate smallpox, vaccine research has remained 
among the top priorities of virology research across the globe. As new diseases are 
discovered, we are learning more about mechanisms of illness at both the global and 
molecular scales, and are today more equipped to fight illness than ever before. However, 
this does not mean that new viruses are of no challenge for scholars in this field. While 
only discovered in the early 1980’s, human immunodeficiency virus (HIV) has grown to 
affect tens of millions of people globally, and development of an HIV vaccine has 
become one of the most sought-out goals of the scientific community. While treatments 
have since become available to fight HIV (which left untreated develops into acquired 
immunodeficiency syndrome, or AIDS), none is sufficient in completely ridding a patient 
of viral particles. The research that is to be presented by this thesis is only a small portion 
of that which has been, and is being conducted, around the world on HIV/AIDS.  
 This project is being conducted to further research in the field of HIV and 
prevention of the virus, by use of a non-human primate model and recombinant genetic 
technology. It is hypothesized that by creating a recombinant simian varicella virus 
(SVV) vaccine expressing the simian immunodeficiency virus (SIV) capsid (gag) and 
envelope (env) protein, and vaccinating the non-human primates on a prime-boost 
method, the animals will be vaccinated against SVV, and in the process will also create 
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antibodies to SIV gag and env protein, effectively immunizing the animal against both  
viruses. The three primary goals of this study are listed as follows: 
-  To optimize conditions for running western blots of vaccinated rhesus sera and 
determine a preferred method of detection of antibodies to SIV capsid (gag) and 
envelope (env) proteins.  
- To compare the efficacy of two different vaccination strategies utilizing a prime- 
boost technique employing the rSVV-SIV vaccine and either an SIV protein or 
SIV DNA vaccine boost.   
- To evaluate the humoral immune response induced by recombinant SVV vaccines 
expressing the SIV gag or env protein in immune naive Macaca mulatta. 
By assessing the efficacy of the existing vaccines, future efforts can be further conducted, 
and even targeted or specified, and ineffective efforts can essentially be omitted from 
future studies. 
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CHAPTER I: BACKGROUND ON HIV/AIDS 
 
 Acquired Immune Deficiency Syndrome was first described in 1981 when there 
was an epidemic among young, homosexual men that was causing opportunistic 
infections and rare types of cancer (Sharp & Hahn, 2011). AIDS was previously known 
as GRID, Gay-Related Immunodeficiency, due to the demographic that was most 
affected, or A.I.D. for Acquired Immunodeficiency Disease. When AIDS was first 
discovered, the CDC and National Cancer Institute said that they were probably only 
seeing “the tip of the iceberg”, due to the idea that the disease was being spread long 
before symptoms were beginning to show (Altman, 1982).  
 As of 2017, almost 37 million people worldwide were living with HIV/AIDS, 
with 1.8 million of them being new infections that year. Only an estimated 75% of these 
citizens knew of their status, pointing to the need of more accessible testing. While the 
proportion of AIDS patients receiving antiretroviral therapy is increasing (up to 59% in 
2017), accessibility and cost of treatment is still a hinderance. Mortality rates have also 
improved, with 940,00 having died from AIDS complications in 2017, compared to the 
almost 2 million people dead in 2004. Though previously mentioned that access to 
effective treatment is an issue, this mortality statistic at least shows that the scientific 
community is indeed moving in the right direction (“Global HIV/AIDS Overview”, 
2019). While the 2010’s have shown great progress with making treatment accessible 
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across the globe, particularly in under-developed countries which are most affected by 
the disease, researchers are not done yet.  
 
Emergence of HIV 
 AIDS is caused by either HIV-1 or HIV-2, with the former being the most 
common. Both viruses are classified as lentiviruses, which can cause chronic and 
persistent infections in several different species of mammals like horses, cats, and 
primates. These viruses integrate into the hosts’ germ cells, allowing it to pass through to 
offspring. Both come from cross-species infection of varying SIV strains, with HIV-1 
specifically resulting from a chimpanzee strain of SIV (SIVcpz). Most primate species 
contain their own, specialized strains of SIV, but cross-species transmission has created a 
plethora of combination strains. When HIV-1 was discovered, one of the scientific 
community’s main goals was to find how the virus suddenly came about. The first clue 
was in 1986 in patients in western Africa, who were diagnosed with HIV-2. Structurally, 
HIV-1 and HIV-2 are very similar. Due to the two strains’ genetic differences, different 
diagnostic methods may be implemented. HIV-2 isn’t often tested for unless the patients’ 
behaviors call for it. HIV-2 is also typically less pathogenic than HIV-1 and less easily 
transmitted (German Advisory Committee Blood, 2016). Though HIV-2 and HIV-1 are 
distantly related, HIV-2 has shown to be very similar to a macaque strain of SIV. Later 
studies showed that this strain, SIVmac, couldn’t have been natural, but was likely 
generated within primate centers in the U.S. while cross-inoculating macaque species 
with sooty mangabey blood and/or tissue (Sharp & Hahn, 2011).  
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 Meanwhile, SIV strains from chimpanzees and gorillas have nearly identical 
genomic structures to HIV-1, of which there are multiple subtypes, each having 
originated in different regions due to various transmission events between individuals of 
different species. The groups include M, N, O, and P, with M being the pandemic group, 
O accounting for less than 1% of total HIV-1 infections, and N and P only causing single- 
or double-digit numbers of infections. There are hypotheses around what species of 
primates these 4 different types of HIV-1 might have originated from, but it is known that 
transmission to humans must have occurred through some exposure to infected primate 
blood either at a mucous membrane or percutaneously (Sharp & Hahn, 2011).  
 
Viral Transmission 
  HIV-1 spreads between individuals through sexual intercourse, percutaneous 
routes such as using infected needles, or during childbirth. Most of the viral transmissions 
take place at mucosal surfaces, such as through sex, classifying HIV-1 as a sexually 
transmitted infection (STI) (Sharp & Hahn, 2011). Transmission by sex involves HIV 
being taken up by macrophages in the mucosal layer of tissue, whether it be rectally, 
vaginally, or orally. If the transmission occurs directly at the site of a wound or to the 
blood stream directly, a much smaller dose is required for infection to occur, and T helper 
cells can be directly infected rather than taking a pathway through M cells in a mucosal 
membrane. Transmission during pregnancy typically occurs in the last trimester, but can 
occur sooner; it can also occur via breast feeding (German Advisory Committee Blood, 
2016).  
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Pathophysiology 
Before discussing how HIV enters cells, it’s important to understand the virus’s 
structure. A mature HIV particle is round, containing an envelope which itself hosts 72 
“knobs” that are composed of trimeric env proteins; the monomers are commonly known 
as the gp120 envelope protein. Those trimers are held onto the membrane by the 
transmembrane gp41 protein. Inside is a cone-shaped capsid made of capsid protein p24, 
a protein which is uncommonly, but at times, used in particular diagnostic tools for HIV 
infection. An HIV virus particle contains 2 identical ssRNA molecules within a core. The 
HIV genome also codes for different regulatory proteins, such as Tat, Rev, Nef, Vif, Vpr, 
and Vpu, which all play a role in replication and pathogenicity (German Advisory 
Committee Blood, 2016).  
Initial infection and viral entry requires several steps of protein binding and 
conformational change. The gp120 glycoprotein of an HIV particle can bind to any host 
cell containing a CD4 receptor. After a conformation change in those proteins, there is 
additional space for the gp120 to bind to CD4’s co-receptor. Following that step of 
binding, yet another conformation change occurs in gp120 and gp41. The gp41 then has 
the ability to form a channel between virus and host, which fuses the two and allows the 
HIV capsid to enter the host. The virus’s genome is synthesized in the host’s cytoplasm 
by using reverse transcriptase, the viral RNA is degraded, and the viral DNA can 
integrate into the host genome to complete viral infection and establish latency. It can 
take as little as 24 hours for the entire process to occur, and for new viruses to be released 
from infected cells. Mode of transmission can also affect the infection’s timeline 
(German Advisory Committee Blood, 2016). 
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Illness and Symptoms 
 Symptoms are usually observed 3-6 weeks post-infection and can vary greatly. 
Most often, however, HIV infection presents as cold or flu, rendering it difficult to 
recognize for someone unaware of their status or risk behavior. Symptoms can last from 
2 weeks to almost 2 months. After initial symptoms, a patient can go into an 
asymptomatic phase for years, and viral load can decrease by millions or even billions. 
One factor that makes HIV so dangerous is this asymptomatic period. Vaginal or seminal 
fluid is still infectious, even when the person shows no symptoms or the viral load is 
virtually undetectable in the blood (German Advisory Committee Blood, 2016). If we 
travel back to the 1980’s, we can get a glimpse into what early researchers or discoverers 
of this disease could have been thinking. People coming into a clinic with flu-like 
symptoms very well could have had HIV, but there were no tests as it was not a known 
disease at the time. Years go by and people’s HIV infections were developing into full-
blown AIDS, while at the same time the disease was being spread at an exponential rate.  
 If HIV goes undetected and untreated, it will eventually result in AIDS. Because 
HIV infects CD4+ cells, it leaves the immune system very weak, hence the term 
“immunodeficiency”; the depleted CD4 supply is the main contender in leaving someone 
prone to further illness (Richman, 2000).  When a person reaches this point, it is not 
necessarily the virus that kills them, but rather what the medical community knows as 
“opportunistic infections.” People come into contact with pathogens on a daily basis, but 
a healthy person with a competent immune system has the ability to fight most of them 
off. An AIDS patient, however, does not, and will experience these infections in much 
more lethal forms. There are also several rare cancers that may be observed in AIDS 
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patients, the most common being Kaposi’s Sarcoma. It is quite possible that a person who 
previously engaged in risky sexual behavior also be infected with other STI’s such as 
forms of herpes or human papillomavirus (HPV), both of which can also result in cancers 
throughout the body of an AIDS patient (German Advisory Committee Blood, 2016). 
 
Diagnosis 
 It is extremely important to be tested for HIV, and other STIs regularly if a person 
is engaging in risky sexual behavior. HIV is diagnosed using 2 main forms of detection. 
These include both antibody and viral detection (HIV GAC). When someone donates 
blood, HIV RNA levels in the blood can be measured using a nucleic acid test (NAT), 
and this can be accurately measured around a week and a half after infection.  
 Antibody detection is the primary screening method for HIV diagnosis, and if the 
primary screening results are positive it is followed up by confirmatory tests such as 
western blot, or immunoblot. ELISA (enzyme linked immunosorbent assay) tests 
containing common HIV-1 subtypes and HIV-2, and sometimes additional antigens, or 
particle agglutination tests are the foremost ways of antibody detection for regular patient 
testing. ELISA is known for giving false-positives, as it is a highly sensitive test, but 
immunoblots have a much lower sensitivity, which can offer a more accurate result in the 
case of a false-positive ELISA (German Advisory Committee Blood, 2016). 
 Viral detection is much more costly and not very quick, so therefore is not used in 
the US anymore for diagnosis. What is observed in virus detection is the p24 antigen. 
Because this is simply shed from infected cells, with no association to the viral nucleic 
acid, no correlation be made with progression of infection and p24 antigen levels. 
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Treatment and Prevention 
 While there is not an absolute method of immunizing against HIV, there are still 
ways to treat the virus post-infection and minimize risk of contracting the virus.  
Early Methods 
 There was about 15 years before any effective antiretroviral treatment developed 
for the fight against HIV, and the most that could be done in that time is try to ward off 
the opportunistic infections and manage the illnesses that come with AIDS infection (Arts 
& Hazuda, 2012). Hospital bills were around $64,000 a patient when HIV was first 
discovered, likely because medical professionals were quite in the dark on HIV/AIDS 
(Altman, 1982). The first antiretroviral treatments targeted reverse transcriptase and 
protease by inhibiting them, and were given independently, rather than a cocktail like 
today’s regimens (Arts & Hazuda, 2012). 
Current Treatment 
 Today, however, we have a quite effective HIV treatment known as highly active 
antiretroviral therapy (HAART), which involves combining multiple antiretroviral 
treatments; today it is the standard of care for HIV patients who are fortunate enough to 
access it. This treatment can lower viral load as much as to make it undetectable, in one 
way by making sure production of new CD4 cells isn’t being inhibited by HIV infection 
(Richman, 2000). Additionally, reverse transcriptase is very error prone, and as many as 
10 mutations can arise in just one replication cycle, creating many HIV-1 variants. 
HAART’s success can also be attributed to its ability to decrease likelihood of selecting 
clones that are extremely mutated. The use of HAART to treat HIV must be maintained 
for the remainder of a patient’s lifetime, or viral rebound can occur. (Policicchio, et al., 
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2016). Past research on patient quality of life and neuropsychological function during 
HAART has been conducted alongside the medical signs of illness. Some studies have 
shown that HAART’s benefits go beyond the effects on the immune system, even in 
patients with advanced-AIDS. Among those benefits were weight gain, which is a good 
sign in AIDS patients, and decreased depression (Brechtl, et al., 2001). Although 
HAART has proved to be a very effective method of treatment, it is still no means to cure 
HIV/AIDS. 
Preventing Transmission 
 There are several ways to help halt the spread of HIV, and other STIs as well. The 
most important steps are to know one’s own HIV status, to practice safe sex, and in 
general to avoid high-risk behavior, such as having multiple partners or using drugs, 
specifically ones injected by needle. Pre-exposure prophylaxis (PrEP) is also an option 
for someone who knows that they are of high risk for contracting HIV. Truvada, an FDA-
approved drug and pre-exposure prophylactic, is a combination of two compounds that 
help prevent HIV particles from taking hold of and infecting cells. If it’s used as 
prescribed on a daily regimen, the risk of getting HIV through intercourse is lowered by 
over 90%, and through infected needles is lowered by around 70%. An infected person 
undergoing treatment for HIV can also exhibit much lower titres of virus, which can help 
prevent the spread of the virus (“Pre-Exposure Prophylaxis”, n.d.).   
 
Research Model and Experimental Counterparts 
Now that effective treatment does exist, the next step is to find an effective mode 
of prevention, and to do this it is necessary to have the proper models for research. There 
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currently exists feline, mouse, and non-human primate models, the latter of which is used 
for conducting the research for this project (Policicchio, et al., 2016). The ultimate goal 
of this research, as mentioned previously, is to create a safe and effective recombinant 
varicella-zoster virus (VZV) vaccine that could also immunize against multiple HIV 
proteins. Studies cannot be conducted on humans prior to success with an animal model, 
due to ethical reasons and the risk of infecting more people than already are. The 
immediate goal, then, is to create a recombinant simian varicella virus (SVV) vaccine 
that also immunizes non-human primates from SIV (rSVV-SIV). This chapter will sum 
up the similarities and differences in HIV and SIV; and VZV and SIV, in order to 
demonstrate the potential efficacy of the simian model.  
 Because HIV originally emerged from primate species, primates are looked at 
as one of the most accurate models for studying HIV. Non-human primates (NHPs) 
relatively larger size also makes for the possibility of larger samples when collecting 
blood and sera (Policicchio, et al., 2016) The study undertaken by our lab in collaboration 
with the Tulane National Primate Research Center utilizes rhesus macaques, Macaca 
mulatta, as do many HIV researchers. Pathogenically, SIV and HIV infection in primates 
and humans, respectively, are very similar. For example, they are common in the way 
they both integrate into host genomes, and the way they distribute across the body in 
multiple tissues. However, with many research models there are still limitations. For 
example, during SIV or HIV-2 infection, NHPs exhibit elevated viral loads, both in acute 
and chronic stages, in comparison to HIV-1 infection in humans. This makes control with 
antiretroviral treatment much more difficult (Policicchio, et al., 2016).  
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 The study presented in this thesis is a continuation of research that has been 
conducted for over a decade. The hypothesis that a rSVV-SIV vaccine would be effective 
against SIV pathogen has been tested previously and proven quite effective. Rhesus 
macaques were inoculated with the recombinant vaccine using a homologous prime-boost 
method, with boosters administered at 35 and 70 days following initial immunization. Six 
months later, the animals were challenged with SIVmac251 intravenously. The 
experimental group of animals showed much higher increases in SIV antibody after the 
challenge, demonstrating that the rSVV-SIV was at the very least effective and eliciting 
an antibody-mediated response in the animals. While all of the animals eventually 
became infected with SIV, an initial reduction in viral load shows promise for this 
experimental model (Traina-Dorge, et al., 2010). 
VZV and SVV  
Despite the possibility of limitations, the Simian model for this study has great 
ability to parallel potential vaccination for humans using VZV as a vector. The varicella-
zoster virus, commonly known as chickenpox, vaccine was first approved for use in the 
United States in 1995. The current regimen has children receive a primary inoculation at 
12-15 months and a booster between 4-6 years of age, both received intradermally. The 
vaccine, known as VZV VARIVAX, is a live, attenuated vaccine derived from a clinical 
isolate known as VZV Oka. It can establish latent infection and later cause shingles, but 
the Zostavax vaccine exists to immunize against that. Though past studies have shown 
that VZV inoculation in non-human models does not create the same type of disease as it 
does in humans, there is a similar disease which affects non-human primates, known as 
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simian varicella virus (SVV). SVV is very similar genetically to VZV, has similar 
pathophysiology, and also establishes latent infection in neural ganglia (Gray, 2013).  
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CHAPTER II: BACKGROUND ON RECOMBINANT VACCINES 
 
The first question that could be asked is: why not use an attenuation method on 
HIV, like many of the other vaccines that have been developed over the past 2 centuries? 
Like with many decisions, there is a balance of cost and benefit, even in vaccine 
development. In the chickenpox vaccine, for example, there is some risk, although very 
minute, that the patient can have a full-blown infection post-inoculation. However, at the 
age of chickenpox vaccination, that disease it not particularly dangerous to the patient, so 
it is worth the small risk to most likely never contract the disease. Attenuating a virus like 
HIV and administering it as a vaccine would be far too dangerous.  Fortunately, 
vaccinology has moved through several waves of new vaccine strategies. It began with 
administration of live virus, then attenuated or killed pathogens, but today’s scientific 
advances are now allowing strategies involving recombinant proteins and recombinant 
genomes. These advances continue to challenge scholars in the vaccinology field to 
develop vaccines that can indeed fend off intracellular pathogens, such as HIV, and it is 
possible that this could be done through use of recombinant vaccine methods 
(Nascimento & Leite, 2012).  
 
Past Successes in Recombinant Vaccinology 
 The utilization of recombinant technology like that in this thesis is not new. 
There are multiple studies that have demonstrated success in, or at least progress towards
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immunization using recombinant methods, and these have also discovered limitations in 
this type of technology. For example, the amount of protein that can be expressed from a 
recombinant vaccine, as well as how it may be translated and/ or modified within a cell 
all matter when developing a recombinant vaccine (Nascimento & Leite, 2012). 
Recombinant Viral Vectors 
 Rather than directly introducing proteins into an individual, using viral 
vectors allows the introduction of a genomic system that can induce an immune response 
upon entrance of the target antigen; this is the method employed in this study, as well. As 
mentioned previously, it is a priority to find vaccination methods that can induce 
intracellular, or even all forms of immune responses, and scientists hypothesize that this 
can be achieved by using recombinant viral vectors. For a virus to be a desirable vector 
for recombinant vaccination, it should have a large enough genome for incorporating new 
genetic material, be genetically stable, have capability of growing large numbers and be 
able to be isolated and purified, lack ability to integrate into host genome, and as always, 
be completely safe. Current viruses that meet these criteria and are currently used for 
vaccine development research include vaccinia, adenovirus, and herpes virus, to name a 
few. This method has been used widely in the development of an effective HIV vaccine. 
One example comes from adenovirus, a non-enveloped, icosahedral virus that invades 
multiple locations across the body. Adenovirus serotype 5 (Ad5) is the strain used, as it 
meets all criteria for a safe and effective viral vector. The HIV antigens expressed by the 
recombinant Ad5 include gag, pol, env, and nef. This system has shown to be quite 
competent in controlling viral infection of SIV in monkeys, even after an HIV-SIV 
challenge. However, after this study moved into human trial, it proved unsuccessful in 
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vaccination against HIV. Additionally, patients who were already immune to Ad5 were 
more likely to become infected by HIV (Nascimento & Leite, 2012). While this may have 
been unsuccessful, it helped progress the entire field closer to a possible cure or vaccine, 
and also demonstrated the limitations of certain models. 
 
Prime-Boost Method 
 Throughout testing of many successful and unsuccessful vaccine 
developments, one fact that is now widely understood is that immunization against a 
disease as complex as HIV/AIDS will most likely require a combination of vaccination 
methods. One such method is prime-boosting, which simply means that multiple 
inoculations are administered over a designated time span. When the same vaccine is 
used in both priming and boosting, it is considered homologous prime-boosting, and if 
varying vaccines are used, it is called heterologous prime-boosting (Nascimento & Leite, 
2012). An example of homologous prime-boosting is the vaccine for VZV. A study 
performed in Germany assessing the efficacy of one-dose vs. two-dose vaccination 
against varicella proved that the homologous prime-boost method was much more 
successful. Children who received the two-dose regimen were much less likely to get 
varicella than those who only received one dose, validating the prime-boost method’s 
potential (Wutzler, et al., 2008).  
 The prime-boost method has shown great potential for vaccine research for 
HIV and is the chosen immunization method used in the research presented by this thesis. 
One such success was demonstrated in an immunization schedule with a priming 
recombinant vaccinia virus expressing SIVmne gp160, followed up by a booster of a 
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recombinant gp160 protein. Success in the prime-boost method was also demonstrated in 
mice which were primed with a DNA vaccine that encoded genetic material from 
influenza, and were boosted with a recombinant poxvirus encoding the same material 
(Nascimento & Leite, 2012). While the mechanisms behind the prime-boost method are 
poorly understood, the scientific community has enough knowledge to continue on 
researching with it in hopes of curing varying infectious diseases. Hopefully with 
different combinations of DNA vaccines, protein vaccines, and recombinant vaccines, the 
right regimen for curing will be eventually be discovered. This thesis explores and 
compares two heterologous prime-boost studies, each employing either a DNA or protein 
vaccine as a booster. 
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CHAPTER III: METHODS AND PROTOCOL OPTIMIZATION 
 
 To target the first aim of this study, various parameters were altered and 
analyzed for quality and/or accuracy based on hypothesized results. Various amounts (0.3 
μg, 0.5μg, and 1μg) of the gag and env proteins were separated on 10-20% tris-glycine 
gels to gauge the minimal protein dilution that can be transferred to a PVDF membrane, 
but that can still provide clear imaging for analysis. Additionally, dilution of primary 
antibody (NHPs LK40 and LK47 at the PB stage) to blocking solution (5% blotto) was 
tested at the 1:100 and 1:200 increments to determine if a higher dilution improved level 
of detection on the blots. These experiments were performed at the onset of this study in 
order to standardize the results, control and experimental, attained throughout the 
remainder of the project, and also assist in attaining the most accurate results in later 
studies. 
 
Experimental Design 
 The study explored in this thesis employs a heterologous prime-boost 
method, rather than a homologous method like previous studies involved with this 
project. Research done under a contract with the National Institutes of Health (NIH) 
Simian Vaccine Evaluation Unit (SVEU) includes a protein vaccine boost, and our other 
study presented here provided by resources from an NIH R01 grant utilizes a DNA 
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vaccine boost. I will focus primarily on the SVEU study, but later compare the results 
between the protein and DNA vaccine boost studies. 
 Sera was taken from the NHPs housed at the Tulane National Primate 
Research Center at multiple points throughout the study for analysis of potential immune 
responses. Sera was taken before initiation of any immunizations to assure that the 
animals were not already infected with SIV (and SVV), and this was confirmed by 
ELISA at TNPRC, and by immunoblot in our lab. The experimental group received 
inoculations of the rSVV-SIV gag and env vaccines at months 0 and 2, and received the 
SIV gag/env protein vaccines at months 6, 9, and 12 (Figure A-5). The animals will have 
been challenged with the macaque strain of SIV (SIVmac251) in month 15, which will 
ideally be administered at a low dose either intrarectally or intravaginally, depending on 
the sex of the animal. Because HIV is primarily sexually transmitted rather than 
intravenously, this method of viral challenge could potentially provide more realistic 
parameters and results than introduction of a high-dose bolus directly into the blood 
stream.  
 
Handling of NHP Sera 
 Working with animal sera can be very dangerous, so it is of the utmost important 
to be cautious when working with it. Any protocol that required direct interaction with 
the test subjects was dealt with at TNPRC. After drawing blood from the animals, sera 
was isolated, frozen, shipped to Oxford, MS, and analyzed in the laboratory at the 
University of Mississippi. Gloves were used at all times while handling any animal sera, 
and any disposable materials that came in contact with the animal sera were disposed of 
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properly. Sera was also heat-inactivated at 56ºC for 30 minutes before being aliquoted 
into separate tubes. Repeated heating and freezing of animal sera could cause the quality 
of target proteins to decrease; aliquoting helps to preserve the quality of the sera. Protease 
and phosphatase inhibitors in the Lamelli sample buffer used for running the proteins 
during gel electrophoresis are also used to help preserve sera and antigen quality (Jensen, 
2012). 
 
Initial Protocol 
A protein molecular weight ladder and one µg of purified gag and env protein, 
each diluted in Lamelli sample buffer, were loaded as according to Figure 1, and 
separated on a 10-well Invitrogen 10-20% tris-glycine gel via sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, a common method of protein analysis also known as 
SDS-PAGE. Gel electrophoresis was carried out in running buffer at 100V and 60mA for 
75 minutes. After electrophoresis, the proteins were transferred to a PVDF membrane 
using pre-prepared transfer buffer at 20V and 180 mA for 75 minutes. The PVDF 
membrane was allowed to air dry, and was cut into separate testing strips (containing the 
molecular weight ladder, controls, and experimental proteins) before storing in the 4ºC 
refrigerator.   
The immunoblot was blocked overnight in a 5% non-fat milk solution, or 
blocking buffer (BB). Following this step, the blot was soaked in 1:200 primary antibody 
(positive or negative control, or non-human primate sera: 5% BB) overnight on a 
gyratory shaker and then washed the next day using wash buffer. Secondary antibody (2º 
Ab) (HRP-conjugated mouse anti-monkey IgG, in 1:1000 dilution to 5% BB) was then 
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added to the blots to soak for 2 hours on the gyratory shaker and then washed again 
before adding 1:1 ECL Clarity luminol:peroxide solution. The enzyme conjugated to the 
2º Ab (horse radish peroxidase) reacts with the peroxide and luminol solution to emit 
light which is detectable by the BioRad Chemidoc system; blots soaked in this solution 
for appoximately 5 minutes and were then dried to image using the BioRad Chemidoc 
system with the “high-resolution” program. The same parameters (program and IV 
exposure time) were used when imaging any western blots, with exception of taking 
additional images at various parameters, such as using “high-sensitivity” for an image 
with low antibody detection.  
A protocol which did not require digital imaging was also performed once at the 
beginning of this study, but it was decided that imaging via chemiluminescence and the 
BioRad system was sufficient for the research being conducted, and was also easier to 
image, store, and organize.  
 
 
Figure 1. Sequence for loading wells prior to performing SDS-PAGE. Throughout 
this study, gels were loaded in a consistent manner so that accurate comparisons could be 
made. The molecular weight ladder (MW) was always loaded in front of the purified env 
and gag proteins. Each PVDF membrane supplied 3 separate blots for later analysis.  
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Protocol Modifications 
Initial protocol instructed that the blots be washed for 2-3 minutes, 5 times, in 2-3 
mL of wash buffer after the 1º Ab and 2º Ab soaks. However, there was less background 
noise in the images when the blots were washed for longer periods, so the protocol was 
later changed to an 8 minute wash, 5 times, in 5mL wash buffer. With this, the 
membranes were also imaged while they were still wet rather than dry, and sometimes 
allowed to dry for reimaging. Dilutions of the protein ran on the gel and of the primary 
antibody were analyzed to see if further minimization of use of these solutions was 
possible. For the gel, 0.3μg, 0.5μg, and 1μg of each protein were ran to see if a difference 
was observed. Primary antibody dilutions were performed at a 1:200 dilution and a more 
concentrated 1:100 dilution.  
 
Optimization of Immunoblot Conditions 
Longer periods of washing as well as imaging while the blot was still wet after the 
luminol and peroxide soak did show better imaging in terms of background noise, so this 
protocol was adopted for the remainder of the blot imaging. There were no consistent 
differences observed between 1:200 vs. 1:100 dilution of primary antibody (Figure 2), so 
it was decided to continue on with the 1:200 dilution, for the purpose of conserving the 
serum stock.  Results from testing various amounts of the gag and env proteins (Figure 3) 
included a noticeable reduction in antibody detection in the blot that was ran with .3μg of 
each protein. The 1μg dilution seemed to be slightly stronger than the .5μg one, so this 
dilution was used throughout the remainder of the project.  
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Figure 2. Western blot analysis using different concentrations of 1º Ab. Blots A and 
B are analyses of NHP LK40 PB serum, at 1:100 and 1:200 1ºAb:5%BB, respectively. 
Blots C and D are analyses of NHP LK47 PB serum, also at 1:100 and 1:200 
1ºAb:5%BB. Various 1ºAb concentrations were analyzed to find a concentration that 
allowed conservation of animal sera, while also producing quality images. 
 
 
  
 
Figure 3. Western blot analysis of varying amounts of gag and env proteins using 
positive control sera. In western blot A, 0.3µg of purified of gag and env protein was 
loaded onto the gel; in blot B, 0.5µg was loaded; and in blot C 1µg of purified protein 
was loaded. All 3 gels were transferred to a PVDF membrane for analysis using positive 
control SIVmac251 serum to assess what amount of protein would allow for the best 
imaging technique. 
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Controls 
Using the above protocol, a positive control blot (Figure 4A) using SIVmac251-
positive sera as the 1º Ab, and a negative control (Figure 4B) using SIVmac251-negative 
sera as the 1º Ab were first attained for later comparison to blot analyses of pre-immune 
(PI), post-prime (PP), and post-boost (PB) sera. The only further modifications made to 
the protocol were for acquisition of a higher-quality negative control blot image (Figure 
3C) for comparison of PI sera.  
 
 
 
Figure 4. Optimization and assessment of negative control blots. Blot A is a positive 
control blot for comparison to blots B and C, which were both analyzed using SIV-
negative control sera. Blots B and C are from separate analyses performed on different 
days. Blot C was obtained using a specialized sterile protocol to attain a higher quality 
and more accurate image. 
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Several images of both negative control blots, as well as analysis of assumedly 
seronegative PI sera showed light streaking on both the env and gag lanes of the blot. 
Due to these results, measures were taken to perform a highly sterile protocol. No dishes 
or tools that previously came in contact with control or experimental sera were used to 
handle the western blots, and fresh sterile petri dishes were used throughout any soaking 
processes to assure that unwanted antibodies were not capable of binding to the 
membrane.  
Another limitation that was encountered while using chemiluminescence and 
digital imaging was that the computer auto-adjusted based on the amount of protein 
detected on the blots, and how bright that the blot was illuminating into the BioRad 
system’s camera, due to protein presence. This limitation was not truly recognized until 
the immune profiles for all of the subjects were completed (Appendix A). Essentially, a 
blot that may have had virtually undetectable amounts of protein, such as our negative 
controls or PI blots appeared very grainy, and even splotchy occasionally, while our 
positive control or PB blots, which were expected to have high antibody detection were 
of much higher quality. Quality of the digital images by the computer was and is 
considered in the results and discussion of further projects in hopes of keeping results 
standardized.  
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CHAPTER IV: HUMORAL RESPONSES INVOKED BY THE RSVV-SIV 
VACCINE 
 
 In the 2nd part of the study, sera from 4 non-human primates from the Simian 
Vaccine Evaluation Unit (SVEU) study at 3 different stages were analyzed by western 
blot to detect presence of antibodies to both the gag and env proteins. The three stages are 
pre-immune (PI), while the non-human primate (NHP) was still immune naïve, or prior to 
exposure to varicella or SIV; post-prime (PP), the period after 3 scheduled inoculations of 
the recombinant SVV-SIV vaccines; and post-boost (PB), or sera taken from the non-
human primates after 2 additional inoculations of a protein vaccine developed by outside 
researchers. For the final project of this study, sera from the post-boost period of non-
human primates which were given a DNA vaccine, rather than a protein vaccine, were 
analyzed by western blot to compare to the NIH SVEU contract animals. 
 
SVEU (Protein Boost) 
A protein vaccine is simply a purified or recombinant protein derived from a 
pathogen with the purpose of eliciting an immune response in the target subject. 
Recombinant protein methods of vaccination have proven quite successful in the fight 
against both Hepatitis B and human papillomaviruses, making recombinant technology a 
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popular choice. Serum from 4 rhesus macaques (LK40, LK43, LK44, and LK47) was 
taken at multiple points throughout this study (pre-immune, or PI; post-prime, or PP; and 
post-boost, or PB), and sent to the lab in Oxford for western blot analysis. The SVEU 
study employs a prime-boost method, using the rSVV-SIV as the priming agent, and the 
protein vaccine as the boosters, which here were purified gag and env proteins, supplied 
by another company and acquired by TNPRC. When analyzing the blots, we expect to 
see bands for the env protein at approximately 140 kDA, and bands for the gag protein at 
51, 27, and 17 kDa.  
Results and Discussion 
 Analysis of the PI blots following imaging showed some questionable results at 
first. There was a double-streaking pattern, seen in the negative control (Figure 5B) as 
well as in some of the NHPs’ sera analyses (Figure 5D-F). Considering these sera were 
taken before the NHPs were exposed to any virus or immunization methods, there should 
have been absolutely no antibody detection or bands on the immunoblot. However, it was 
determined that there was a certain amount of antibody detection present even on the 
negative control (Figure 4), so any streaking patterns or bands present on the negative 
control were also considered irrelevant in the immune profile presented on the western 
blots.  This assumption was made also in conjunction with TNPRC’s negative ELISA test 
results for the animals prior to any immunizations. The grainy appearance of the blots 
could also indicate a low amount of antibody binding on the membrane. 
 
 
 
 
 28 
 
 
Figure 5. Western blot analysis of SVEU NHP PI sera. A molecular ladder (A) is used 
in evaluating any blots for env and gag antibody detection, while a negative control (B) is 
used for specifically assessing PI blot analyses (C-F) from SVEU NHPs LK40, LK43, 
LK44, and LK47, respectively. Anything showing on the negative control blot is 
henceforth omitted from experimental analyses. 
  
 
 
The main goal of analyzing the post-prime sera (Figure 6) was to assess the strength of 
the immune response before and after boosting. Based off of the quality of the images, 
there were likely low levels of antibody detected in PP analyses compared to the PB 
analyses (Figure 7), except for NHP LK43 (Figure 6C).  The quality of the images of PB 
sera analyses (Figure 7) likely indicate that there was a sufficient amount of antibody 
bound to the membranes prior to imaging, demonstrating that the strongest immune 
response came after the protein boost. 
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Figure 6. Western blot analysis of SVEU NHP PP sera. A positive control blot (A) is 
included for comparison in any blots that are expected to have positive env and gag 
antibody detection, such as with PP and PB analyses. Experimental blots (B-E) were 
analyzed using SVEU NHP LK40, LK43, LK44, and LK47 PP sera, respectively.  
 
 
 
 
Figure 7. Western blot analysis of SVEU NHP PB sera. Blots B-E, analyses of SVEU 
NHPs LK40, LK43, LK44, and LK47 PB sera, respectively, are compared against the 
positive control (A) for env and gag antibody detection.  
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DNA Boost Analysis 
 DNA vaccines have been used for HIV studies for the majority of the time 
HIV vaccine research has been conducted, most likely due to their ability to evoke cell-
mediated immunity (Chen, et al., 2014). DNA immunization involves using genetic 
engineering to encode antigens on a plasmid, and then inoculating a person or subject 
with that genetic material. The desired genes are coupled with a promoter, and are either 
injected percutaneously or shot into the skin using a gene gun. The genes are expressed in 
cells that take up the plasmid, as well as any antigen presenting cells (APC’s) that 
recognize them as well. The plasmid will only express the desired protein, a target 
antigen, and will not incorporate into the host genome. After cells take in the plasmid, the 
encoded genes can be expressed and presented on major histocompatibility complexes 
(MHC). While this method has been successful in smaller animal models, DNA 
vaccination has not yet been promising with humans. However, immunogenicity of these 
vaccines have been improved by modifying the vector. It is recognized that DNA 
vaccination could be an important step for immunization against HIV, as it is safe even 
upon repeated inoculation (Khan 2013). 
A new cohort of NHPs was used in the DNA vaccine study, which also employed 
a prime-boost method for rSVV-SIV vaccination, but with use of a DNA vaccine booster, 
rather than protein vaccination used in the SVEU study. The DNA vaccine was composed 
of a plasmid which encoded the genes for both gag and env proteins. The sera analyzed 
from this cohort of animals was only from the PB period. Comparison of the results from 
the SVEU study (Figure 7) and R01 study (Figure 8) demonstrates that a protein vaccine 
is overall more successful in eliciting an immune response, in terms of resulting in 
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immunogenicity to both target proteins. After boosting with the DNA vaccine, there was 
strong gag antibody detection but little to no env antibody detection. Meanwhile, the 
protein-boosted immunization schedule elicited a very strong response to env and, while 
less prominent than the env response, there was still a detectable amount of antibody to 
gag present in the sera.  
 
  
 
 
Figure 8. Western blot analysis of R01 NHP PB Sera. Blots B-D, analyses of R01 
NHPs LL83, LM28, and LM48, respectively, are compared against the positive control 
(A) for detection of env and gag antibodies.  
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CONCLUSION AND FUTURE EFFORTS 
 
 Through using different methods or making modifications throughout the research 
process, the protocol for detection of antibodies to gag and env protein created in 
response to the rSVV vaccine by western blot was ultimately optimized. The protocol 
modification testing period also showed us that there is flexibility in several aspects of 
the protocol, allowing it to be well suited to different time frames and parameters. Data 
collected throughout the semester shows that the prime-boost strategy using a protein 
vaccine seems to induce a stronger immune response than the DNA vaccine boost. For 
more accurate results, our strategy could be carried out in the future with a larger cohort. 
Repeat imaging including a longer wash period would also increase the quality of some 
of the blot images. 
 Up to the present, only sera from non-human primates that were immune-naive 
prior to their respective vaccination strategies have been analyzed via western blot. There 
is, however, a potential study which includes an additional group of non-human primates 
which have previously been exposed to SVV before vaccination that can be tested, which 
would show the effects of pre-existing SVV antibodies on the recombinant vaccine’s 
ability to illicit an immune response. This model will hopefully shed insight to the 
immune response to a theoretical recombinant VZV-HIV vaccine administered after a 
person has already been exposed to varicella. 
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 Currently, the vaccine only includes the structural gag and env genes, but has 
potential for addition of new models as well. Our lab is currently working to develop a 
DNA vaccine and a rSVV vaccine, each of which includes the “Retanef” (rev, tat, nef) 
genes. Tat is the primary activator in transcription, Rev regulates RNA splicing and the 
export of viral RNA, and nef is an accessory gene which has affects on replication, 
budding, and pathogenicity (German Advisory Committee Blood, 2016). The hypothesis 
for this study is that adding the Retanef vaccine to the current cocktail will help increase 
the humoral response that the gag and env are already eliciting. This recombinant 
technology will continue to be modified, and has been, is being, and will likely be used 
for future research in vaccinology, and not only restricted to HIV cure research. The 
overarching goal of this project was to contribute to HIV research via an SIV model, and 
the findings show hope towards one day finding a vaccine for HIV. 
 
 
  
 34 
APPENDIX 
 
 
 
Figure A-1. Gag and env antibody detection of NHP LK40 at the PI, PP, and PB 
stage of immunization. Blots C-E are compared with the negative control (A) and 
positive control (B) for the absence or presence of antibodies to the target antigens.  
 
 
 
 
Figure A-2. Gag and env antibody detection of NHP LK43 at the PI, PP, and PB 
stage of immunization. Blots C-E are compared with the negative control (A) and 
positive control (B) for the absence or presence of antibodies to the target antigens.
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Figure A-3. Gag and env antibody detection of NHP LK44 at the PI, PP, and PB 
stage of immunization. Blots C-E are compared with the negative control (A) and 
positive control (B) for the absence or presence of antibodies to the target antigens. 
 
 
 
 
Figure A-4. Gag and env antibody detection of NHP LK47 at the PI, PP, and PB 
stage of immunization. Blots C-E are compared with the negative control (A) and 
positive control (B) for the absence or presence of antibodies to the target antigens. 
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Figure A-5. Immunization schedule of the R01 grant and SVEU contract rhesus 
macaques.  The stars indicate the time periods from which the lab received sera samples 
from the animals, while the upward-pointing arrows  indicate the time periods at which 
animals underwent vaccinations, SIV challenge, or euthanization. 
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